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Abstract
Exosomes are endosome-derived small membrane vesicles that are secreted by most cell types including tumor cells.
Tumor-derived exosomes usually contain tumor antigens and have been used as a source of tumor antigens to stimulate
anti-tumor immune responses. However, many reports also suggest that tumor-derived exosomes can facilitate tumor
immune evasion through different mechanisms, most of which are antigen-independent. In the present study we used a
mouse model of delayed-type hypersensitivity (DTH) and demonstrated that local administration of tumor-derived
exosomes carrying the model antigen chicken ovalbumin (OVA) resulted in the suppression of DTH response in an antigen-
specific manner. Analysis of exosome trafficking demonstrated that following local injection, tumor-derived exosomes were
internalized by CD11c+ cells and transported to the draining LN. Exosome-mediated DTH suppression is associated with
increased mRNA levels of TGF-b1 and IL-4 in the draining LN. The tumor-derived exosomes examined were also found to
inhibit DC maturation. Taken together, our results suggest a role for tumor-derived exosomes in inducing tumor antigen-
specific immunosuppression, possibly by modulating the function of APCs.
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Introduction
Tumor cells usually express tumor-specific or tumor-associated
antigens which are potentially immunogenic [1], however
established tumors are able to induce immunosuppression and
even tolerance to these antigens. Various tumor immune evasion
strategies have been identified including both antigen-specific and
non-specific mechanisms [2,3,4]. Release of exosomes by tumor
cells has been recognized as one of the mechanisms through which
tumor cells can suppress the anti-tumor immune responses [5,6].
Exosomes are 30–100 nm small membrane vesicles formed by
the reverse budding of the multivesicular bodies in the late
endocytic compartment and are released upon the fusion of
multivesicular bodies with the plasma membrane [7,8,9]. Tumor-
derived exosomes usually contain tumor antigens [6,10,11,12,13]
and therefore have been used as a novel source of tumor antigens
for cell-free cancer vaccines [11,14,15]. Indeed, induction of
protective anti-tumor responses has been observed when tumor-
derived exosomes were used to pulse mature DCs or when the
exosomes applied were isolated from tumor cells genetically
modified to express proinflmmatory cytokines or have elevated
levels of stress proteins [11,16,17,18,19]. Targeting antigens to the
exosome membrane surface also appears to enhance the
immunogenicity of tumor-derived exosomes [20,21].
However, it is also noticed that although tumor-derived
exosomes are produced abundantly in the tumor microenviron-
ment, an effective immunostimulatory role of tumor-derived
exosomes has not been well observed in cancer patients with
advanced disease. Instead, increasing lines of evidence suggest that
tumor-derived exosomes may actually facilitate tumor immune
evasion. For example, tumor-derived exosomes have been
reported to negatively regulate the functions of effector T cells
and NK cells, as well as inhibit the differentiation of DCs
[13,22,23,24,25,26,27]. They were also found to promote the
generation of myeloid-derived suppressor cells and enhance the
activities of regulatory T (Treg) cells [13,28,29,30]. Moreover, pre-
treatment of tumor-derived exosomes promoted tumor growth in
certain murine tumor models [26,31]. These findings suggest that
tumor-derived exosomes have immunosuppressive properties
which could aid tumor escape from host immunosurveillance.
Notably, most of the immunosuppressive effects conferred by
tumor-derived exosomes reported to date are in antigen-
independent contexts.
Interestingly, exosomes secreted by certain non-tumor cell types
have been observed to induce antigen-specific immunosuppression
in several animal models. For example, exosomes derived from
immature DCs deliver self MHC molecules as alloantigen to
MHC-mismatched recipient and induce donor-specific T cell
tolerance, resulting in prolonged allograft survival [32]. Also,
exosomes derived from antigen-pulsed intestinal epithelial cell can
induce antigen-specific tolerance in naı¨ve recipient animals [33].
Similarly, exosome-like vesicles purified from different biological
fluids of animals sampled with certain antigens were found to
suppress antigen-specific immune responses [34,35,36].
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In this study, we investigated the ability of exosomes derived
from two murine tumor cell lines expressing the model antigen,
chicken ovalbumin (OVA), to modulate OVA-specific immune
response in a murine delayed-type hypersensitivity (DTH) model.
We demonstrate that local administration of these exosomes, but
not their OVA negative counterparts, induces suppression of
OVA-specific DTH response. Suppression of the DTH response
was associated with elevated levels of TGF-b1 and IL-4 mRNA in
the draining LN. Also, the tumor exosomes were internalized by
CD11c+ cells in vivo and were able to affect the maturation and
function of DCs in vitro. Overall, our results demonstrate the ability
of antigen-containing tumor-derived exosomes to confer immu-
nosuppression specific to that antigen.
Results
Characterization of tumor exosomes
Exosomes were purified from the culture supernatants of two
mouse tumor cell lines stably expressing the OVA antigen, the
thymoma line EG7 and the melanoma line MO5, and their
respective parental cell lines EL4 and B16. Electron microscopy of
the purified exosomes showed typical vesicular structures ranging
from 30 to 120 nm in diameter (Fig. 1A). Western blot analysis
showed that compared with whole cell lysates, exosomes were
relatively enriched in the MVB markers Alix and Tsg101. Other
common exosome proteins including Hsc70, Hsp90, high mobility
group box-1(HMGB1) and b-actin were also detected (Fig. 1B).
Full-length OVA protein was detected as a doublet form of around
40 to 45 kDa by immunoprecipitation in both EG7 and MO5 cell
lysates, as well as in EG7 and MO5 exosomes. OVA was absent in
EL4 and B16 cell lysates and their exosomes (Fig. 1C).
Additionally, FACS analysis showed that MHC class I molecules
(H-2Kb) were only present at marginal to undetectable levels on
these exosomes, although they were expressed on cells at different
levels. These exosomes were also negative for MHC class II
molecules (I-Ab). CD81 was present on B16 and MO5 exosomes,
but only at marginal levels on EL4 and EG7 exosomes (Fig. 1D).
Taken together, these results show that exosomes derived from
each pair of tumor cell lines are similar in both morphology and
protein content except for the presence of OVA.
Local administration of OVA-containing tumor exosomes
induces suppression of the OVA-specific DTH response
We previously demonstrated that plasma-derived exosomes
from mice sensitized with a certain antigen were able to suppress
antigen-specific inflammatory response when administered locally
[34]. To examine if tumor-derived exosomes are able to regulate
antigen-specific immune response, we investigated the effect of
OVA-containing tumor exosomes on OVA-specific DTH re-
sponse when administered similarly into a mouse footpad model.
Briefly, C57BL/6 mice were immunized against OVA protein.
Three weeks post-immunization, the mice were injected with
10 mg of exosomes or saline control in the right hind paws and
were challenged with OVA in both hind paws. The magnitude of
the DTH response was determined by measuring footpad swelling
24 h and 48 h post-challenge. Interestingly, we observed that EG7
exosome treatment significantly reduced paw swelling by more
than 50% compared with saline treatment at both time points
(Fig. 2A). In contrast, EL4 exosomes were not as effective in
suppression. To determine the effect of OVA-containing exosomes
in the absence of OVA challenge, sensitized mice were treated
with EL4 or EG7 exosomes only in the right hind paws while the
contralateral, left hind paws were challenged with OVA. In fact,
treatment with EG7 or EL4 exosomes alone did not cause paw
swelling, comparing to the contralateral paws that had significant
swelling (Fig. 2A). These results suggest that OVA-containing
tumor exosomes are able to suppress the OVA-specific immune
response, and that tumor exosomes themselves do not induce
inflammatory responses. Suppression of the OVA DTH response
by EG7 exosomes was reproducible in repeated experiments
(Fig. 2B). Moreover, treatment with MO5 exosomes was also able
to decrease paw swelling by 50% compared with PBS treatment
whereas B16 exosomes were not effective in suppression (Fig. 3).
Taken together, these results demonstrate that local administration
of EG7 and MO5 exosomes are able to induce suppression of an
OVA-specific Th1-type inflammatory response. The ineffective-
ness of EL4 and B16 exosomes in inducing suppression suggests an
important role of exosome-contained antigens in conferring the
suppressive effect.
Interestingly, the reduction of swelling in the treated paws by
either EG7 or MO5 exosome treatment was always accompanied
by a comparable reduction in the contralateral, untreated paws. A
similar ‘‘contralateral effect’’ (i.e. distal therapeutic effect) has been
observed following intra-articular gene transfer of immunosup-
pressive cytokines, inhibitors of IL-1b and TNF-a, or NF-kB
decoy oligonucleotides in rabbit or mouse models of arthritis and
DTH [37,38,39,40,41]. More recently, we have demonstrated the
similar effect in mouse arthritis and DTH models following
footpad delivery of DC-derived exosomes [42,43]. Although the
exact mechanism for how local delivery confers a contralateral
effect is still unclear, our observation with tumor exosomes
suggests that the suppression conferred by tumor exosomes can
affect systemic immune responses.
OVA-containing tumor exosomes do not induce
suppression of KLH-specific DTH response
To further determine whether EG7 and MO5 exosome-induced
suppression of DTH response is antigen-specific, we investigated if
these exosomes were able to suppress the DTH response elicited
by an irrelevant antigen, keyhole limpet hemocyanin (KLH). To
test this, mice pre-sensitized with KLH were treated with tumor
exosomes and challenged with KLH using a similar protocol.
However, both EG7 and MO5 exosomes were found ineffective in
reducing footpad swelling, and the magnitudes of KLH-specific
DTH responses were comparable between exosome treated
groups and the saline control group (Fig. 4). This result
demonstrates that the suppressive effect of EG7 exosomes and
MO5 exosomes is restricted to the OVA-induced DTH response
and thus is antigen-specific.
Exosomes are internalized by CD11c+ cells and traffic to
the draining LN after local administration
To investigate the potential mechanism of the antigen-specific
suppression conferred by tumor exosomes, we examined the
trafficking of exosomes and their interaction with immune cells in
vivo after footpad injection. Exosomes were labeled with the green
fluorescent linker PKH67 and injected into the right hind paw of
OVA-sensitized mice at the time of antigen challenge. The
footpads and popliteal LNs were isolated 24 h or 48 h post-
injection and analyzed by immunofluorescence. In the footpad
tissue, co-localization of exosomes and CD11c+ cells, which
appear to be mostly dermal DCs, was observed (Fig. 5A). At 24 h
post-injection, a significant proportion of CD11c+ cells with
internalized exosomes were found in the treated-side LN (Fig. 5A).
At 48 h post-injection, the labeled exosomes were found mostly
internalized into CD11c+ cells and localized in the CD3+ T cell
area in the treated side LN (Fig. 5B). The contralateral LN was
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also examined to see if there was bilateral lymphatic cross-
trafficking of exosomes. However, very few exosomes were
observed in the contralateral LN (Fig. 5B). Significant trafficking
of exosomes to the spleen was not observed following local
injection (data not shown). Furthermore, exosome treatment did
not increase the number of apoptotic cells in the draining LNs
compared with PBS treatment, as determined by TUNEL staining
(Fig. 5C), suggesting that the suppressive effect does not directly
result from increased lymphocyte apoptosis.
Suppression of the DTH response is associated with
increased TGF-b1 and IL-4 mRNA levels in the draining
LN
Given that a large number of exosomes were found in the
draining LN after exosome treatment, we next examined the
cytokine profile in the draining LN to determine if DTH
suppression was associated with the up-regulation of regulatory
cytokines. Treated-side popliteal LNs were isolated 48 h after
treatment with EL4 exosomes, EG7 exosomes or PBS and OVA
challenge. The mRNA levels of several cytokines were analyzed by
qRT-PCR. The TGF-b1 and IL-4 mRNA were found both
significantly elevated in mice treated with EG7 exosomes,
compared with mice treated with EL4 exosomes or PBS
(Fig. 6A–B). Correspondingly, mice treated with EG7 exosome
had reduced IFN-c mRNA level compared with mice treated with
PBS (p = 0.07, Fig. 6D). Interestingly, an increase in IL-10 mRNA
level was found not only in the EG7 exosome group, but also in
the EL4 exosome group (Fig. 6C). To determine if such cytokine
pattern is related to the induction of Foxp3+ Tregs, the Foxp3
mRNA level was also examined. Although EG7 exosome group
showed the highest average Foxp3+ mRNA level, the increase
compared with the other two groups was not significant (Fig. 6D).
These results suggest that within the time frame of DTH response,
elevated levels of TGF-b1 and IL-4 mRNAs are associated with
exosome-induced suppression. However, significant expansion of
Foxp3+ Tregs was not induced.
Tumor exosomes inhibit DC maturation and induce TGF-
b1 production
The trafficking study showed that after local injection tumor
exosomes were internalized by CD11c+ cells, most of which are
comprised of DCs. DCs play an essential role in antigen-
presentation and the initiation of antigen-specific immune
responses. In a typical DTH response, immature DCs acquire
and process exogenous antigens, and differentiate into mature
DCs which are able to present antigens and co-stimulatory signals
to memory T cells to initiate the response. Therefore we further
examined whether these tumor exosomes could affect DC
maturation and function. Briefly, day 8 bone marrow-derived
DCs (BMDCs) were treated with 10 mg/ml of exosomes for 3 days
and the expressions of MHC class II molecules and co-stimulatory
molecules were examined by FACS analysis. Interestingly,
treatment with each of the four tumor exosomes tested all resulted
in the down-regulation of MHC class II molecules (I-Ab) and
CD86 (Fig. 7A), suggesting that in the presence of tumor exosomes
the spontaneous maturation of DCs can be inhibited. Moreover,
Figure 1. Characterization of tumor exosomes. (A) EM micrographs of exosomes isolated from EL4, EG7, B16 and MO5 cell culture supernatants.
(B) Western blot analysis of exosomes and cell lysates. 10 mg of proteins were loaded per lane. (C) IP detection of OVA protein (40,45 kD) in both cell
lysates and exosomes. (D) FACS analysis of MHC class I, MHC class II and CD81 expression on cells and exosomes.
doi:10.1371/journal.pone.0022517.g001
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exosome treatment induced TGF-b1 production in DC culture
(Fig. 7B). The TGF-b1 levels in the exosomes were determined to
be 10–15 pg per 10 mg of exosomes (Fig. 7C), which was
significantly less than the total amount increased in DC culture,
indicating that the increased TGF-b1 was produced by DCs in
response to exosome treatment. These results further demonstrate
that tumor exosomes have inhibitory effect on DC maturation and
are able to induce the production of regulatory cytokine by DCs. It
also suggests that tumor exosomes may have the ability to
condition DCs toward a tolerogenic phenotype.
Discussion
Whether tumor-derived exosomes, usually carrying tumor
antigens, are immunostimulatory or immunosuppressive can be
controversial according to the existing reports [6,11,12,13,16,
17,18,19,20,21,22,23,24,25,26,27,28,29,31]. It is also unclear if
tumor-derived exosomes can regulate immune response specifi-
cally against the tumor antigens they carry. In the present study,
we demonstrate that exosomes derived from tumor cells stably
expressing the model antigen OVA, were able to induce
suppression of the OVA-specific DTH response. Interestingly,
the suppression of DTH response was observed only with antigen-
containing tumor exosomes and was specific to the immune
response induced by that particular antigen.
The mouse model used in this study is a footpad model of DTH,
which represents a type of Th1-dominant cell-mediated response.
We have reported previously that exosomes derived from
genetically modified DCs expressing exogenous IL-10, IL-4 or
FasL could suppress murine DTH response and alleviate collagen-
induced arthritis, demonstrating that DC-derived exosomes can be
potent therapeutic agents to suppress inflammatory responses
[42,43,44]. Here we examined the immunosuppressive effect of
tumor-derived exosomes using a similar DTH model. In the two
pairs of tumor cell lines examined, the EG7 and MO5 cells stably
express OVA and secrete full-length OVA protein into their
exosomes. We observed down-regulation of OVA-specific DTH
Figure 2. Suppression of OVA-specific DTH response by local administration of EG7 exosomes. (A) Mice pre-sensitized with OVA were
injected with 10 mg of EL4 exosomes plus 30 mg of OVA, 10 mg of EG7 exosomes plus 30 mg of OVA, 30 mg of OVA alone, 10 ug of EL4 exosomes
alone or 10 ug of EG7 exosomes alone in 50 ml of PBS in their right hind paws. The left hind paws were all challenged with 30 mg of OVA in 50 ml of
PBS. Paw swellings of both treated (right) and contralateral (left) paws were measured 24 h and 48 h post-challenge as the increase in footpad
thickness (60.01 mm). The results shown are from one representative experiment and are the means 6 SD with n = 5. (B) The mean increase of
footpad thickness of the treated paws in PBS group (OVA alone) at each time point was set to 1, and the increases of footpad thickness in EL4
exosomes plus OVA group and EG7 exosomes plus OVA group were normalized as fold increase. Figures show the pooled results of three
independent experiments and are the means 6 SD with n = 15. Significance at **: P,0.01; *: P,0.05; NS: not significant.
doi:10.1371/journal.pone.0022517.g002
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response when introducing EG7 or MO5 exosomes into the
footpad in the elicitation phase, whereas the non-specific KLH-
induced DTH response was not suppressed by these exosomes.
These results suggest that tumor-derived exosomes are able to
confer immunosuppression, at least in this particular model, in an
antigen-specific manner.
We further examined exosome trafficking in the DTH
experiment and found that tumor exosomes injected locally were
predominantly internalized by dermal CD11c+ cells, which then
migrated to the draining popliteal LNs. Because of the limited cell
number in individual popliteal LN, the cytokine profile in the LN
was analyzed by qRT-PCR. We found that DTH suppression by
exosomes was associated with significantly higher TGF-b1 and IL-
4 mRNA levels in the LNs. In contrast, the Th1 inflammatory
cytokine IFN-c mRNA level was greatly reduced (Fig. 6). TGF-b1
is known to block the activation of lymphocytes and monocytes,
and has been shown to convert effector T cells into Treg cells [45].
It was also implicated in the inhibition of murine DTH response
[46], suppression of antigen-specific Th1-type responses and the
generation of a suppressive Th2-type response [47]. The Th2
cytokine IL-4 has been shown to suppress DTH response [48] as
well as to support the differentiation of TGF-b-producing cells
[49]. Although the exact cell type(s) producing these cytokines
remains to be determined, these cells seem to be activated after
administration of antigen-containing tumor exosomes in an
antigen-specific manner. The increased IL-10 mRNA level in
EL4 exosome-treated group was somewhat unexpected, since the
DTH response was not efficiently suppressed. However it could
suggest a non-specific effect of tumor exosomes, which might not
be sufficient for effective suppression without the induction of
TGF-b1 and IL-4.
Based on our observation that exosomes were internalized
predominantly by CD11c+ cells and since CD11c+ DCs play a key
role in initiating antigen-specific immune response, we further
examined the effect of these tumor exosomes on DCs. Indeed,
treatment with tumor exosomes down-regulated the expression of
Figure 3. Suppression of OVA-specific DTH response by local administration of MO5 exosomes. Mice pre-sensitized with OVA were
injected with 10 mg of B16 exosomes, 10 mg of MO5 exosomes or PBS alone in their right hind paws and were challenged with OVA at both hind
paws. Paw swellings were measured 24 h and 48 h post-challenge. (A) Representative results showing the increase in footpad thickness (60.01 mm)
of treated and contralateral paws. n = 5. (B) Pooled results of two independent experiments showing the fold increase in footpad thickness as
compared to the treated paws in PBS group. n = 10. **: P,0.01; *: P,0.05; NS: not significant.
doi:10.1371/journal.pone.0022517.g003
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MHC class II molecules and CD86 on BMDCs and induced
TGF-b1 production by DCs in culture (Fig. 7). The inhibitory
effect of tumor-derived exosomes on DC differentiation from BM
precursors has been reported [27]. Our findings suggest that
tumor-derived exosomes can also inhibit the maturation of
differentiated DCs and may predispose DCs to acquire a
potentially suppressive or tolerogenic phenotype. Therefore, DCs
are likely to play an important role in mediating exosome-
conferred DTH suppression. Notably, the non-specific effect of
tumor exosomes on DCs suggests the potential involvement of an
antigen-specific cell population activated by exosome-conditioned
DCs. One possible mechanism for the observed antigen-specific
immunosuppression is that DCs preferentially acquire exosome-
contained OVA antigen and present antigen in a manner that
favors the activation of antigen-specific Tregs. Although the qPCR
data suggest that there was no significant induction of Foxp3+ in
the draining LN after exosome treatment (Fig. 6), the percentage
of CD4+Foxp3+ Tregs usually increases in both splenic and LN
CD4+ T cells after OVA immunization (data not shown).
Therefore it is possible that the existing OVA-specific Tregs can
be more efficiently activated by DCs presenting exosome-derived
OVA antigen. It is also possible that regulatory cells other than
Fox3+ Tregs are involved [50].
Interestingly, although EL4 and B16 exosomes showed similar
effects on DCs in vitro, they were not as effective as EG7 and MO5
exosomes in suppressing OVA-specific DTH responses. This could
be due to the fact that the OVA antigen delivered to DCs in the
context of exosomes is presented more efficiently than the
challenge antigen. It has been mentioned that particulate antigen
can be more efficiently presented by MHC class II molecules than
soluble antigen [51,52]. Thus the OVA present in tumor exosomes
may be more efficiently acquired by DCs at the same time as the
tumor exosomes drive them towards a suppressive phenotype.
This hypothesis is consistent with the ineffectiveness of both sets of
exosomes in suppressing KLH-specific DTH response, which
further suggests that the presence of the inciting antigen in
exosomes is needed for effective immunosuppression.
In addition to APC internalization, exosomes may also directly
interact with memory T cells after local injection in the DTH
model. In fact, a direct effect of tumor exosomes on primed T cells
Figure 4. OVA-containing tumor exosomes were not effective in suppressing KLH-specific DTH response. Mice pre-sensitized with KLH
were treated with 10 mg of exosomes or PBS in their right hind paws and were challenged with KLH antigen at both hind paws. Paw swellings were
measured 24 h and 48 h later. The increases in footpad thickness (60.01 mm) of one representative experiment (n = 5) (A) and the normalized fold
increases in footpad thickness of two independent experiments (n = 10) (B) are shown. NS: not significant.
doi:10.1371/journal.pone.0022517.g004
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or antigen-specific T cell hybridoma was not observed (data not
shown). The tumor exosomes examined all express low levels of
MHC molecules (Fig. 1) and thus may have limited ability to
present OVA epitopes on their surface to directly activate specific
T cells. Similarly, treatment with tumor exosomes alone with no
challenge antigen did not elicit local inflammatory responses in
antigen-sensitized mice (Fig. 2A). These observations also suggest
that very likely tumor exosomes regulate antigen-specific T cell
responses indirectly through an APC-mediated mechanism.
The accompanied suppression of DTH response in contralateral
paws after treatment with antigen-containing tumor exosomes is
similar to our previous observation of a suppressive contralateral
effect in the DTH model following local injection of DC-derived
or plasma-derived exosomes [34,42,44]. The contralateral effect
could be conferred by several possible mechanisms including the
spreading of exosomes or the migration of functionally altered
cells. The trafficking analysis demonstrated that only a few
exosomes was present in the contralateral LN, consistent with a
recent report that tumor exosomes preferentially home to LN
ipsilateral to the injection site [53]. Therefore, the contralateral
effect is likely not mediated by direct spreading of exosomes. We
have demonstrated previously that adoptive transfer of APCs
generated from antigen sensitized, Ad.vIL-10 treated mice can
inhibit local and distal DTH reactions in recipient mice sensitized
to the same antigen [54]. In addition, endogenous DCs were
implicated in the pathogenesis of rheumatoid arthritis (RA) in a
SCID mouse arthritis model where unilateral implantation of
human RA synovium resulted in a bilateral knee joint disorder
[55]. These results both suggest the active involvement of
trafficking APCs in the systemic spread of immunomodulatory
effects. We hypothesize that local exosome delivery is able to
functionally alter the activity of a subset of immunoregulatory
cells, such as APCs, that in turn can suppress the immune response
at distant sites in an antigen-specific manner.
Taken together, our studies demonstrate that tumor-derived
exosomes bearing a model tumor antigen can confer antigen-
specific immunosuppression in a murine DTH model. Although
this model does not necessarily reflect the behavior of tumor-
derived exosomes in tumor-bearing hosts, it highlights a potential
role of antigen-containing tumor exosomes in inducing antigen-
specific tolerance. Our results also suggest the possibility of
utilizing tumor-derived exosomes containing certain antigen to
Figure 5. Exosome in vivo trafficking in DTH model. PKH67-labeled exosomes were injected in the right footpad of OVA-sensitized mice as in
the DTH experiment. Footpads and the popliteal LNs were harvested, cryo-sectioned and examined by immunofluorescence. Similar observations
were made with different tumor exosomes and data show the representative figures of MO5 exosomes. (A) 24 h post-injection, exosomes (green)
were captured by dermal CD11c+ cells (red) in footpads and transported to the treated-side LN. (B) 48 h post-injection, large numbers of exosome-
internalized CD11c+ cells (red, upper left panel) appear in the treated-side LN. Exosomes (or exosome-containing cells) were also physically adjacent
to CD3+ T cells (red, lower left panel). Only very few exosomes were observed in the contralateral LN. (C) TUNEL staining for apoptotic cells (red) in
both side LNs 48 h post-injection. Magnification: 206.
doi:10.1371/journal.pone.0022517.g005
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suppress antigen-specific inflammatory response. However, it is
also important to note that the nature of antigen and the way it is
presented on or in exosomes may affect the immunogenicity of
exosomal antigen [20,21]. In addition, how tumor-derived
exosomes affect immune response could be regulated by different
environmental conditions. Although further studies are still needed
to address the underlying cellular and molecular mechanisms and
to determine whether tumor-derived exosomes bearing natural
tumor antigens could function similarly, our results report the
novel finding that tumor-derived exosomes are able to induce
antigen-specific immunosuppression and provide a new insight
into the important role they could play in mediating tumor
immune evasion.
Materials and Methods
Cell lines
The C57BL/6-derived thymoma cell line EL4 and melanoma
cell line B16-F0 (B16) were obtained from American Type Culture
Collection. The EL4-OVA (EG7) [56] and B16-OVA (MO5) [57]
cell lines were generously provided by Dr. Walter Storkus
(University of Pittsburgh). Cells were cultured in RPMI-1640
supplemented with 10% FBS, 2 mM of L-glutamine, 0.1 mM of
non-essential amino acids, 1 mM of sodium pyruvate, 10 mM of
HEPES, Antibiotic-Antimicotic (100 U/ml penicillin, 100 mg/ml
streptomycin and 0.25 mg/ml amphotericin B, GIBCO), and
50 mM of 2-mercaptoethanol. The EG7 and MO5 cell lines were
under G418 selection (0.8 mg/ml and 1.5 mg/ml, respectively).
Cell lines were tested to be free of mycoplasma.
Mice
Female C57BL/6 mice (H-2Kb) at 6–8 wk of age were
purchased from Jackson Laboratories. Animals were maintained
in a pathogen-free animal facility at University of Pittsburgh
Biotechnology Center. All animal experiments were conducted
according to protocol 0804421B-1 approved by the University of
Pittsburgh Institutional Animal Care and Use Committee.
Exosome purification
Exosomes were purified from cell culture supernatant. FBS used
in culture media for exosome isolation was pre-cleared by
ultracentrifugation at 100,0006 g for 3 hr at 4uC. 48 hr culture
supernatants were centrifuged at 10006 g for 10 min and
10,0006 g for 30 min, filtered through 0.22 mm sterilizing filter
Figure 6. qRT-PCR analysis of cytokines and FoxP3 mRNA levels in the draining popliteal LN associated with DTH suppression.
Panels show the relative mRNA levels of TGF-b1 (A), IL-4 (B), IL-10 (C), IFN-c (D) and FoxP3 (E) normalized to b-actin mRNA level in the treated-side
popliteal LNs 48 h after EL4 exosomes, EG7 exosomes or PBS treatment at the time of OVA challenge. n = 5. **: P,0.01; *: P,0.05; NS: not significant.
doi:10.1371/journal.pone.0022517.g006
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(Corning), and concentrated using Centricon Plus-70 (100 kD
cutoff) filter units (Millipore). Exosomes were pelleted by
ultracentrifugation at 100,0006 g for 1.5 hr, washed with sterile
PBS, and pelleted again by ultracentrifugation at 100,0006 g for
1.5 hr. Exosomes were then resuspended in PBS and quantified by
Bradford protein assay (Bio-Rad).
Transmission electron microscopy
Purified exosome preparations were loaded on Formvar/carbon-
coated grids and negatively stained with 1% uranylacetate. Photos
were taken on a JEM-1011 transmission electron microscope.
Western blotting and immunoprecipitation
Cell lysates or exosomes (10 mg of proteins) were separated by
12% or 10% SDS-PAGE, transferred onto PVDF membranes
(Millipore), blocked and incubated with different primary Abs,
followed by HRP-conjugated secondary Abs (Santa-Cruz).
Protein bands were visualized using an ECL detection kit
(PerkinElmer Life Science). The primary Abs used were: Alix
(3A9) from Biolegend; Tsg101 (C-2), HSC70 (B-6) and HSP90a/
b (H-114) from Santa-Cruz; HMGB1 from GeneTex; and b-
actin from Abcam. For OVA detection, 200–300 mg cell lysates
or exosomes (pre-lysed with NP-40 lysis buffer) were incubated
with rabbit anti-OVA (Chemicon) for overnight at 4uC. Then
40 ml of 50% Protein A-Sepharose beads were added and
incubated for 4 h at 4uC. The beads were washed and the Ab-
bound complexes were eluted by boiling the beads in SDS
loading buffer for 5 min. Proteins were resolved by 10% SDS-
PAGE and detected by Western blotting using mouse anti-OVA
(OVA-14, Sigma) and anti-mouse secondary Ab (stripped from
Figure 7. Tumor exosomes inhibit BMDC maturation and induce TGF-b1 production. (A) Day 8 BMDCs (purity .90%) were treated with
10 mg/ml of tumor exosomes or cultured untreated for 3 days. The expression of I-Ab and CD86 were analyzed by FACS. LPS treatment (1 mg/ml) for
24 h was used as a DC maturation control. (B) TGF-b1 protein levels (pg/ml) in DC culture supernatants after exosome treatment. Data show the
mean values of two independent experiments 6 SD. (C) TGF-b1 contents in exosome preparations (pg/10 mg of exosomes). For each exosome
sample, the data shown represent the mean value of three preparations 6 SD.
doi:10.1371/journal.pone.0022517.g007
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blots previously incubated with rabbit anti-OVA (Abcam) and
anti-rabbit secondary Ab).
Flow cytometry
For exosome surface staining, exosomes were incubated with
aldehyde/sulfate latex beads (1% solids, Invitrogen) at 4uC for
overnight. The reaction was stopped with 100 mM Glycine.
Beads were washed twice in flow buffer (1% FBS in PBS) and
stained with PE-I-Ab (AF6-120.1, BD), or PE-CD81 (Eat2, BD),
or biotin-H-2Kb (AF6-88.5.5.3, eBioscience) followed by strepta-
vidin-PE (eBioscience). Tumor cells were stained with the same
Abs. For surface staining of BMDCs, cells were washed and
stained with FITC-CD11c (N418, eBioscience) and PE-CD86
(GL1, BD), or PE-CD11c (N418, eBioscience) and FITC-I-Ab
(AF6-120.1, BD). Beads and cells were analyzed on BD
FACScanTM flow cytometer. Results were analyzed by the
Flowjo software.
Induction of DTH response and exosome treatment
Mice at 8–9 wk of age were sensitized with OVA antigen by
intradermal (i.d.) injection of 150 mg of OVA (grade V, Sigma)
1:1 emulsified in Complete Freund’s Adjuvant (CFA, Pierce) at
the tail base. 14 days later, mice were boosted by 50 mg of OVA
(grade V, Sigma) 1:1 emulsified in Incomplete Freund’s Adjuvant
(IFA, Pierce). 7 days later, the right hind paw was i.d. injected
with 10 mg of exosomes and 30 mg of OVA (grade II, Sigma), or
exosomes only, in 50 ml of PBS. The left hind footpad was
injected with 30 mg of OVA alone in 50 ml of PBS. Footpad
thickness was measured using a spring-loaded caliper (Dyer)
before, 24 h and 48 h post-challenge. Paw swelling was
determined by the increase in footpad thickness. The KLH-
specific DTH response was induced by sensitizing the mice with
100 mg of KLH (Sigma) 1:1 emulsified in CFA, and challenging
the mice with 20 mg of KLH in the footpad 14 days later. Each
set of experiment was performed with 5 mice per group and
repeated 2–3 times.
Analysis of exosome in vivo trafficking by
immunofluorescence
Exosome labeling with the green fluorescent linker PKH67
(Sigma) was done according to the manufacturer’s guidelines.
50 mg of labeled exosomes were injected into the right hind paw of
OVA-sensitized mice along with OVA antigen. Mice were
euthanized 24 h or 48 h post-injection. Footpads and popliteal
LNs were isolated and fixed in 2% paraformaldehyde and then in
30% sucrose. Fixed tissues were cryo-sectioned and stained with
anti-mouse CD11c or CD3 (BD), followed by GaH-Cy3. Nuclei
were stained with DAPI (Molecular Probes). TUNEL staining was
performed using a Terminal Transferase kit plus biotin-16-dUTP
and streptavidin-Cy3 (Roche). Photos were taken on an Olympus
Provis fluorescence microscope.
Quantitative reverse transcription-PCR
Popliteal LNs were isolated and snap frozen in liquid nitrogen.
Total RNA was purified using the PureLinkTM Micro-to-Midi
Total RNA Purification System (Invitrogen), and treated with
DNase I (Ambion). RNA quality and quantity were measured on a
NanoDrop micro-volume spectrophotometer (Thermo Scientific).
Reverse transcription was done using the SuperScriptTM III First-
Strand Synthesis SuperMix for qRT-PCR (Invitrogen). Quantita-
tive PCR was performed on an iCycler (Bio-Rad) using SYBRH
GreenERTM qPCR SuperMix for iCyclerH (Invitrogen). The primers
used include: TGF-b1 forward 59-TGAGTGGCTGTCTTTT-
GACG-39 and reverse 59-AGCCCTGTATTCCGTCTCCT-39;
IL-4 forward 59-ACAGGAGAAGGGACGCCA-39 and reverse 59-
GAAGCCCTACAGACGAGCTCA-39; IL-10 forward 59-AAG-
GACCAGCTGGACAACAT-39 and reverse 59-TCATTTCCGA-
TAAGGCTTGG-39; IFN-c forward 59-GCGTCATTGAATCA-
CACCTG-39 and reverse 59-TGAGCTCATTGAATGCTTGG-39;
Foxp3 forward 59-TCTTGCCAAGCTGGAAGACT-39 and re-
verse 59-GGGGTTCAAGGAAGAAGAGG-39; and b-actin for-
ward 59- GACGGCCAGGTCATCACTAT-39 and reverse 59-
AAGGAAGGCTGGAAAAGAGC-39. Data were analyzed by
iCycler iQ analysis software (Bio-Rad). Relative mRNA expression
was normalized to the level of b-actin mRNA and calculated using
the DDCT method.
Generation of BMDCs and exosome treatment
Bone marrow cells were flushed out from tibias and femurs of
10–12 wk old mice and a single cell suspension was prepared.
Erythrocytes were depleted with ACK cell lysing buffer. Cells were
cultured in complete media with 20 ng/ml of GM-CSF and
20 ng/ml of IL-4 (PeproTech) in 6-well-plate at the density of
26106 cells/5 ml/well. For every 3–4 days, each well was
replenished with 2 ml of fresh media as well as GM-CSF and
IL-4. Cells were cultured until day 8, when suspended and semi-
adherent cells were collected and the purity of CD11c+ cells was
examined by FACS. Cells were then cultured in 12-well-plate at
16106 cells/2 ml/well and treated with 10 mg/ml of exosomes or
left untreated for 3 days. 1 mg/ml of LPS was added to untreated
cells for the last 24 h as a DC maturation control. Cells were then
harvested and analyzed by FACS.
ELISA
TGF-b1 levels in culture supernatants and exosome prepara-
tions were measured using the mouse TGF-b1 ELISA kit
(eBioscience) upon acidification.
Statistics
DTH results were analyzed by Student’s t-test (between two
groups) or one-way ANOVA (multiple groups). qRT-PCR results
were analyzed by Mann-Whitney U test. A value of p,0.05 was
considered statistically significant. All tests were conducted in the
SPSS statistical software.
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